The science of
Digital Drugs™

Neuroplasticity is at the core of our mode of action. Humans develop and learn by processing information from the external and internal world.

The senses are the natural interfaces by which information is acquired. This information travels to the brain where it is integrated and stored. This process occurs at the level of cells called neurons by changes in the way they connect and communicate (neuroplasticity). In many diseases, altered communication between neuron populations and brain regions are involved or the source of pathology.

Software as a Drug™ by Ababax

By now, hundreds of apps exist that provide access to health services (via doctor-on-demand or communication platforms), support health professionals in diagnostics and data analytics or help patients manage their symptoms with digital companions.

However, while these apps support existing therapies, they are not focused on tackling disease causes. The next wave of digitalization will develop Software as a Drug solutions that go a step further by providing treatment, thereby offering a better risk-benefit profile over existing treatment options.

Software as a Drug is pure software, which on its own has a relevant physiological effect in a comparable manner to the standard of care. Ababax‘ Digital Drugs are streamed and delivered using commercially available devices, making them highly accessible and adaptable to the patients‘ individual needs.

Digital Drugs™ by Ababax

Digital Drugs are software-generated sensory stimuli delivered via non-medical customer devices designed to exploit the senses as an entry point to the brain, inducing neuroplasticity-mediated changes. Using the senses, Digital Drugs have access to deeply embedded brain structures that remain inaccessible to established non-invasive brain stimulation methods. Our new brain stimulation technique leverages anatomy and physiology to cure diseases and restore health.

Exemplary representation of the sensory stimulation pathway using the visual system

Natural entry points

The Digital Drug stimuli enter the brain through the eye. Visual inputs originating from the retina are then transmitted to the visual cortex (Yu et al., Cells, 2021). 

Digital Drug pathway

The visual cortex further projects dorsally to the posterior parietal cortex or ventrally to the inferior temporal cortex, where they interconnect to the prefrontal cortex and limbic structures (Yu et al., Cells, 2021).

Therapeutical effects

This sensory pathway targets brain regions involved in several pathologies able to induce selective neuronal activity and vascular changes, leading to the modulation of neurotrophic expression, neuroplasticity and inflammatory processes.

We leverage the senses to reach the deepest brain structures

Generate targeted stimuli via easy-to-access consumer devices

Stimuli are delivered via general purpose actuators

Stimuli impact targeted physiological processes

Restore health condition of the patient

Ababax develops tailored non-invasive deep stimulation techniques to edit pathological pathways in the brain, unlocking mental and physical health. We leverage the natural entry points to reach relevant brain structures without using dedicated medical hardware. This innovative mode of action targets the neurological and physiological causes of disorders, utilizing brain plasticity to restore connectivity in the central nervous system.
Furthermore, Ababax’s Digital Drugs can be streamed and delivered using commercially available non-medical devices (e.g., smartphones, smart glasses and other wearables), making this therapy highly accessible and adaptable to patients worldwide without any hardware logistics.


therapy for brain related diseases

Directly targeting affected brain circuits

No dedicated Hardware required

Treatment by streaming

Real time personalized

Effortless treatment

Next generation standard-of-care

Significantly reduced CO2 emissions